Advertisement
U.S. markets closed

Adial Pharmaceuticals, Inc. (ADIL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8250-0.0550 (-6.25%)
At close: 03:59PM EST
0.8500 +0.03 (+3.03%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close0.8800
Open0.8489
Bid0.8319 x 1000
Ask0.8440 x 1300
Day's Range0.7775 - 0.8900
52 Week Range0.7775 - 15.0000
Volume185,613
Avg. Volume310,415
Market Cap1.372M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-8.9800
Earnings DateMar 28, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ADIL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adial Pharmaceuticals, Inc
    Daily – Vickers Top Buyers & Sellers for 01/12/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • ACCESSWIRE

    Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

    CHARLOTTESVILLE, VA / ACCESSWIRE / February 15, 2024 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention ...

  • GlobeNewswire

    Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

    Expands patent estate covering Adial’s unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependenceCHARLOTTESVILLE, Va., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it has been awarded an important patent which expands the estate co

  • GlobeNewswire

    Adial Announces Appointment of Tony Goodman as Chief Operating Officer

    Highly Experienced Pharma Commercial and Business Development Executive in Addiction Treatment Space Joins Leadership Team While Continuing as Board MemberCharlottesville, Va., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Tony Goodman as Chief Operating